|
Carcinoma of lung
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear.
|
24035431 |
2013 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutated lung cancer is relatively aggressive and is resistant to currently available therapies.
|
25706985 |
2015 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutated lung cancer is a genetically distinct subtype that occurs in 2-5% of non-small cell lung carcinomas (NSCLC).
|
28625649 |
2017 |
|
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
|
29723688 |
2018 |
|
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
A group of thoracic oncology experts in the field of thoracic oncology met to describe the standard for biomarker testing for lung cancer in the Canadian context, focusing on evidence-based recommendations for standard-of-care testing for <i>EGFR</i>, anaplastic lymphoma kinase (<i>ALK</i>), <i>ROS1</i>, <i>BRAF V600</i> and programmed death-ligand (PD-L1) at the time of diagnosis of advanced disease and <i>EGFR T790M</i> upon progression.
|
29507487 |
2018 |
|
Carcinoma of lung
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.
|
22743296 |
2012 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Accordingly, the combination of MEK inhibitor with EGFR inhibitor was effective at shrinking tumors in mouse model of BRAF non-V600E mutant lung cancer.
|
29348459 |
2018 |
|
Carcinoma of lung
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
|
19238210 |
2009 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although >90% of BRAF mutations in melanoma involve codon 599 (57 of 60), 8 of 9 BRAF mutations reported to date in NSCLC are non-V599 (89%; P < 10(-7)), strongly suggesting that BRAF mutations in NSCLC are qualitatively different from those in melanoma; thus, there may be therapeutic differences between lung cancer and melanoma in response to RAF inhibitors.
|
12460918 |
2002 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although a few Caucasian lung cancer patients harbored BRAF mutations, there have been no reports about the BRAF mutation in Japanese patients with lung cancer.
|
16376942 |
2006 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
ATM loss also enhances the sensitivity of KRAS- or BRAF-mutant lung cancer cells to MEK inhibition.
|
27922010 |
2016 |
|
Carcinoma of lung
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
BRAF and RAS mutations in human lung cancer and melanoma.
|
12460918 |
2002 |
|
Carcinoma of lung
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
|
22798288 |
2012 |
|
Carcinoma of lung
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
|
21483012 |
2011 |
|
Carcinoma of lung
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
|
23833300 |
2013 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
|
25273224 |
2015 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Combined genomic and proteomic analyses demonstrated infrequent alteration of validated lung cancer targets (including the absence of BRAF mutations in TTF1-negative LUAD), but identified novel potential targets for TTF1-negative LUAD, including KEAP1/Nrf2 and DNA repair pathways.
|
25878335 |
2015 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Consistent with earlier reports, our results show that KRAS and BRAF mutation frequencies in colorectal cancer were 44.3% and 13.0%, respectively, while EGFR mutations were detected in 11.1% of the lung cancer specimens.
|
21943394 |
2011 |
|
Carcinoma of lung
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
|
22608338 |
2012 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
|
29516752 |
2018 |
|
Carcinoma of lung
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Genetic predictors of MEK dependence in non-small cell lung cancer.
|
19010912 |
2008 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.
|
30224342 |
2019 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this study, using both novel and established technologies, we developed a clinically practical assay to survey the status of three frequently mutated genes in lung cancer (EGFR, K-ras and TP53) and two genes (BRAF and β-catenin) with known hotspot mutations in many other cancers.
|
22407457 |
2012 |